You are here

Press Releases from AlphaMed Press

September 16, 2021

Durham, NC ( September 16, 2021 ) – A study released in STEM CELLS Translational Medicine (SCTM), by researchers at the Baker Institute for Animal Health, part of Cornell University’s College of Veterinary Medicine, Ithaca, N.Y., details in a relevant ex vivo model how treating wounds with the secretion of a type of stem cell called mesenchymal stromal cell (MSC) effectively reduced methicillin-resistant Staphylococcus aureus – better known as MRSA viability and stimulated the surrounding skin cells to build up a defense against the bacterial invader.

August 24, 2021

Durham, NC (August 24, 2021) – New information from a study reported on in STEM CELLS might result in more effective treatments for osteoarthritis and other cartilage diseases, as well as hereditary disorders affecting cartilage development. Their findings might also point to a new way to accelerate stem cell differentiation for bioengineering cartilage, the researchers say. 

August 18, 2021

Durham, NC (August 18, 2021) – A new phase I clinical study shows, for the first time, how treatment with a type of stem cell called mesenchymal stromal cells is able to regulate important factors driving inflammation in patients with chronic obstructive pulmonary disease (COPD) for a period for time. The study, whose results were released in STEM CELLS Translational Medicine, provides insights that may aid in developing a new cellular therapy for treating COPD which is among the top five causes of morbidity and mortality worldwide – and other chronic airway diseases.

, ,
August 16, 2021

Durham, NC (August 16, 2021) – Tendon injuries in sheep that were treated with stem cell grafts achieved, in just two months, a diameter and hardness similar to the original healthy tendon, according to the results of a study released in STEM CELLS Translational Medicine (SCTM). These findings suggest that the treatment, which uses autologous adipose micrografts – grafts of stem cells derived from fat taken from the recipient – presents a safe, reliable and relatively fast way to promote tendon healing.

August 3, 2021

Durham, NC (August 3, 2021) – A study released in STEM CELLS Translational Medicine has confirmed the safety of a novel type of cellular therapy for knee pain caused by osteoarthritis. Conducted by a multi-institutional team of researchers in Japan who had developed the new therapy, the study was designed to confirm that their treatment – which involves transplanting the patient’s own mesenchymal stem cells (MSCs) into the affected knee – did not cause tumors.

July 27, 2021

Durham, NC (July 27, 2021) - Results of a compassionate-use study released in STEM CELLS Translational Medicine show promising results for treating muscular dystrophies with mesenchymal stem cells (MSCs) derived from Wharton's jelly (WJ), a substance found in the umbilical cord. Led by doctors at Klara Medical Center (KMC), Czestochowa, Poland, these WJ-MSC treatments resulted in significant improvement in several body muscles in most of the patients, with no serious side effects.

July 13, 2021

July 6, 2021 -  Oxford University Press (OUP) and AlphaMed Press are pleased to announce that OUP will publish three AlphaMed Press journals: The Oncologist, STEM CELLS, and STEM CELLS Translational Medicine beginning January 2022.

The Oncologist is a 26-year-old monthly, peer reviewed open access publication committed to helping cancer physicians excel in the constantly changing fields of oncology and hematology through the publication of timely reviews, original studies, and commentaries. The journal aims to help oncologists understand a range of disciplines by connecting translational research and clinical practice but also looks at the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.

June 21, 2021

Durham, NC (June 21, 2021) - A team led by researchers at Newcastle University, UK has successfully created a model of the cells found in the lungs that can be used to replicate how COVID-19 infects the airways. This information, reported today in the STEM CELLS journal, paves the way for broader studies of viral lung infections using a cost-effective system that can easily be manufactured on a large scale.

June 8, 2021

Durham, NC ( June 8, 2021 ) - Critically ill COVID-19 patients treated with non-altered stem cells from umbilical cord connective tissue were more than twice as likely to survive as those who did not have the treatment, according to a study published today in STEM CELLS Translational Medicine.

The clinical trial, carried out at four hospitals in Jakarta, Indonesia, also showed that administering the treatment to COVID-19 patients with an added chronic health condition such as diabetes, hypertension or kidney disease increased their survival more than fourfold.

June 3, 2021

Durham, NC (June 3, 2021)-- Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in STEM CELLS Translational Medicine.

In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabetes. In each case, the cells were autologous, or taken from the patients' own bodies.

A total of 30 adult patients with different body mass indexes whose Type 2 diabetes histories varied from one to 25 years were recruited for the study. Each received two infusions of the cells intravenously or by injection into an artery that supplies blood to the pancreas.